Liraglutide — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 8 sources[1,2,3,4,5,6,7,8].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | A randomized, controlled trial of 3.0 mg of liraglutide in weight management | New England Journal of Medicine | 2015 |
| 2 | Liraglutide and cardiovascular outcomes in type 2 diabetes | New England Journal of Medicine | 2016 |
| 3 | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised… | The Lancet | 2009 |
| 4 | Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily… | Journal of Medicinal Chemistry | 2000 |
| 5 | Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or… | JAMA | 2022 |
| 6 | Mechanisms of action and therapeutic application of glucagon-like peptide-1 | Cell Metabolism | 2018 |
| 7 | WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information | FDA Approved Labeling | 2024 |
| 8 | GLP-1 receptor agonists: reminder of the risk of hypoglycaemia and of use only for licensed indications | MHRA Drug Safety Update | 2023 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2016;375(4):311–322. doi:10.1056/NEJMoa1603827 · PMID 27295427
- Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). The Lancet 2009;374(9683):39–47. doi:10.1016/S0140-6736(09)60659-0 · PMID 19515413
- Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thøgersen H, Wilken M, Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry 2000;43(9):1664–1669. doi:10.1021/jm9909645 · PMID 10794683
- Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 2022;327(2):138–150. doi:10.1001/jama.2021.23619 · PMID 35015037
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001 · PMID 29617641
- United States Food and Drug Administration. WEGOVY (semaglutide) injection, for subcutaneous use — Highlights of Prescribing Information. FDA Approved Labeling 2024;Reference ID revision 01/2024. identifier not held by the Institute
- Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reminder of the risk of hypoglycaemia and of use only for licensed indications. MHRA Drug Safety Update 2023;17(3). identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.